StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
099750.KQ$6900.00-2.13%
Fair $6900.00+0.0%

099750.KQ

ezCaretech Co., LTD

Healthcare / Health Information ServicesKOSDAQ

$6900.00

-150.00 (-2.13%)

Fairly Valued+0.0%Fair Value $6900.00Fund rank 31/100 · Data gapFallback financials|
SA 43/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $4.2B · quality 55.3/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 27/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

43/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 099750.KQLocal privado en este navegador · ezCaretech Co., LTD
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$94.2B

P/E

40.5x

↑

EV/EBITDA

19.9x

↑

ROE

6.3%

↑

Gross Margin

21.8%

↓

Debt/Equity

0.08

↓
52-Week Range$6900
$6770$11800

TradingView lightweight chart

099750.KQ price, volumen y niveles de valoración

Último $6,900Periodo -56.8%
Fair value: $6,900

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-7.6%

FCF CAGR

—

FCF margin

14.6%

FCF / Net income

4.63x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $72.64B · net income $2.29B · FCF $10.61B

2022-FY → 2025-FY

Gross margin

21.8%+3.1% pts

Operating margin

3.0%+2.4% pts

Net margin

3.2%+6.6% pts

FCF margin

14.6%+20.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$72.64B$72.64B$67.94B$73.19B$92.07B
Net Income$2.29B$2.29B$1.21B$-9.59B$-3.19B
EBITDA$4.41B$4.41B$3.56B$-6.81B$261.1M
EPS170.50170.5090.00-759.00-255.00
Gross Margin21.8%21.8%17.6%14.0%18.7%
Operating Margin3.0%3.0%0.3%-5.6%0.6%
Net Margin3.2%3.2%1.8%-13.1%-3.5%
Balance Sheet
Debt/Equity0.080.080.070.200.21
Current Ratio2.062.06———
Cash Flow
Free Cash Flow$10.61B$10.61B$4.20B$-2.00B$-5.20B
Returns
ROE6.3%6.3%3.5%-28.1%-10.1%
Valuation
P/E40.4740.4793.61——
EV/EBITDA19.8719.8729.98—949.71
P/B2.532.533.255.047.88
Growth & Yield
Revenue Growth6.9%6.9%-7.2%-20.5%—
EPS Growth89.4%89.4%111.9%-197.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

53.1%

muy exigente

EPS terminal req.

$612.26

Spread vs growth

36.3%

5Y implied EPS CAGR

34.2%

muy exigente

EPS terminal req.

$740.83

Spread vs growth

55.3%

10Y implied EPS CAGR

21.5%

exigente

EPS terminal req.

$1193.12

Spread vs growth

68.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -23.3%

Total return

-23.3%

Start / end P/E

99.9x → 40.5x

EPS bridge

90.00 → 170.50

Residual

-53.2%

EPS growth+89.4%
Multiple rerating-59.5%
Dividend+0.0%
Residual / FX / buybacks / cross-term-53.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.